Locke Bryan

Locke Bryan serves as Associate Professor in the Department of Medicine (Hematology and Oncology division) at the Medical College of Georgia, Augusta University, with active clinical, teaching, and research responsibilities across hematology and oncology disciplines.

His academic foundation includes:

• MD in Medicine from University of Mississippi (2008)
• Internal Medicine Residency and Chief Residency at University of Vermont
• Hematology/Oncology Fellowship at Northwestern University (2012-2015)

Research focuses intensely on lymphoma pathogenesis and treatment innovation, particularly Hodgkin's and non-Hodgkin's lymphomas, B/T/NK-cell neoplasms, and immunodeficiency-related disorders. His immunotherapy work explores novel mechanisms to enhance T-cell therapies and overcome treatment resistance through oxidative stress modulation and receptor signaling manipulation.

Recent publications reveal strong emphasis on translational lymphoma research, with 2021-2022 studies examining intratumoral immunotherapies for follicular lymphoma, leukemic transformation patterns in ALK-negative lymphomas, chemotherapy-induced immunosuppression mechanisms, and targeted agents like copanlisib. Key themes include tumor microenvironment manipulation, novel combination strategies, and biomarker-driven therapeutic approaches.

Major recognitions include:

• Three consecutive MCG Faculty Exemplary Teaching Awards (2018-2020)
• AACR/ASCO Vail Workshop selection for clinical cancer research methods (2014)
• Appointment to American Society of Hematology Trainee Council (2014)

Teaching encompasses medical student and resident education through courses RHON 5000, RMED 5000, and PHAS 5227, with committee service spanning Augusta University Health System's Clinical Performance/Utilization Workgroup, Compliance/Audit/Ethics Committee, Peer Review Committee, and Pharmacy and Therapeutics Committee since 2017.

Research activities are embedded within Augusta University's academic medical ecosystem, leveraging clinical trial infrastructure and translational research teams focused on hematologic malignancy therapeutics development.